CGAS and STING inhibitors not only have therapeutic value for autoimmune inflammation and AID, such as AGS, FCL, SAVI, and SLE, but also have potential therapeutic value for more common diseases induced by abnormal cGAS-STING pathway activation, such as non-alcoholic steatohepatitis, chronic obstructive pulmonary disease, and Parkinson’s disease. The gene discussed is JAG1; the disease is metabolic dysfunction-associated steatohepatitis.